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Background: Canadians of Chinese descent, represent one of the fastest growing visible minority groups in
Canada, (as well as the second largest), but relatively little is known about the clinical features of heart failure (HF)
in Chinese-Canadian versus non-Chinese Canadian patients.
Methods: We conducted a population-based analysis of urban patients hospitalized in Ontario, Canada for the first
time with a most responsible diagnosis of HF between April 1, 1995 and March 31, 2008. Among the 99,278
patients, 1,339 (1.3%) were classified as Chinese using a previously validated list of Chinese surnames. Through
linkage to other administrative databases, we compared the clinical characteristics, pharmacological management,
and outcomes of Chinese versus non-Chinese HF patients.
Results: Ischemic heart disease was identified as the possible etiology of HF in a greater proportion of non-Chinese
patients (47.7% vs. 35.3%; p < 0.001) whereas hypertension (26.1% vs. 16.1%; p < 0.001) and valvular heart disease
(11.6% vs. 7.2%; p < 0.001) were relatively more common in Chinese patients. Chinese patients were prescribed
angiotensin-converting enzyme (ACE) inhibitors less frequently (57.5% vs. 66.4%, p < 0.001) and angiotensin receptor
blockers (ARBs) more frequently (17.4% vs. 8.9%, p < 0.001) compared to non-Chinese patients. They were also less
likely to be adherent to ACE inhibitors over a 1-year follow up period. However, the 1-year case-fatality rates were
comparable between the Chinese (31.7%) and non-Chinese (30.2%) subjects (p = 0.24).
Conclusion: There are important differences in the causes and medical management of HF in Chinese and
non-Chinese patients residing in Canada. Despite these differences, the long-term outcomes of HF patients
were similar.
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Heart failure (HF) is a source of substantial mortality
and morbidity. However, the impact of HF on specific
ethnic populations has seldom been studied [1]. Chinese
Canadians constitute 4.7% of the Ontario population and
represent 21% of its visible minority [2] population and
yet, little is known about the clinical features of HF in
Chinese patients, relative to other Canadians. In a retro-
spective study of 404 Chinese patients and 1,129 white pa-
tients referred to an urban tertiary care cardiology clinic* Correspondence: tu@ices.on.ca
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tients than in white patients [3]. Chinese patients diag-
nosed with HF generally exhibited higher left ventricular
ejection fractions than white patients. In a cohort study in-
volving six communities across the United States, Chinese
participants demonstrated lower incidence rates of HF
than African American, Hispanic, and white participants
[4]. A previous study from Alberta demonstrated that
Chinese heart failure patients in Alberta had higher ad-
justed 1-year mortality rates than South Asian or non-
Asian patients [5]. Evaluating differences in the treatment
and outcomes of HF among ethnic groups could poten-
tially contribute to our understanding of disease processes
and guide prevention and treatment strategies. This study
compared the clinical characteristics, management andLtd. This is an open access article distributed under the terms of the Creative
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population-based cohort of HF patients in Ontario, Canada.
It builds upon previous studies which focused predomin-
antly on incidence or mortality outcomes alone.
Methods
Study setting
Our cohort included patients who were hospitalized for
the first time due to HF in Ontario, Canada between
April 1, 1995 and March 31, 2008. As of 2006, Ontario
accounted for 38.5% of the Canadian population with
12.0 million people. Individuals who identified them-
selves as Chinese constituted 4.7% of the Ontario popu-
lation and represented one of the largest visible minority
groups in the province, second to South Asians [2].
Sources of data
Hospitalization data were obtained from the Canadian In-
stitute for Health Information Discharge Abstract Database.
Data on prescription drug use for patients 65 years of age
or older were compiled from the Ontario Drug Benefit
Database. Mortality data were determined through the
Ontario Registered Persons Database. The immigration sta-
tus of the study participants was determined through link-
age to the Permanent Resident Database of Citizenship and
Immigration Canada, with recent immigrants identified as
those who immigrated to Ontario after 1984.
Cohort construction
We identified patients from the Discharge Abstract
Database using diagnosis codes from the International
Classification of Diseases, Ninth Revision, Clinical Modi-
fication (ICD-9 CM) and the Tenth Revision (ICD-10).
An audit of the database showed 96% accuracy in the
coding of HF based on the Framingham diagnostic cri-
teria [6]. A total of 292,733 patients were hospitalized
with a most responsible diagnosis of HF (ICD-9 code
428 or ICD-10 code I50) between April 1, 1995 and
March 31, 2008. We excluded patients who were not
residents of Ontario (n = 2,606), lacked a valid Ontario
health card number (n = 2,229), or were less than 20 or
over 105 years of age (n = 828). We also excluded pa-
tients whose HF was listed as an in-hospital complication
(n = 1,842). Patients transferred to another hospital were
only counted once, with subsequent admissions (n = 6,705)
linked to the index event. To identify first instances of HF
requiring hospital admission, we excluded hospitalizations
for HF that occurred up to five years prior to the index ad-
mission (n = 156,056). Hospitalizations occurring more
than five years after the index admission and thus not
representing the first admission in the study period were
also excluded (n = 2,076). All patients hospitalized in rural
hospitals (n = 21,113) were removed from the analysis due
to the low number of Chinese patients in these settings.Classification by Chinese ethnicity
A previously validated list of 1,133 Chinese surnames was
used to identify patients of Chinese ethnicity prior to
anonymization of the hospital discharge data [7]. This list
has been shown to have a sensitivity of 80.6% and a posi-
tive predictive value of 92% in classifying individuals who
previously identified themselves as Chinese from primary
data sources.
Patient characteristics
Demographic information including age and sex were
obtained for the Chinese and non-Chinese groups.
Comorbid disease status was quantified using the
Charlson-Deyo Comorbidity Index, a commonly used
measure of comorbidity burden [8-10]. Prevalence of
cardiovascular comorbidities not accounted for by the
index such as atrial fibrillation or atrial flutter, hyperten-
sion, ischemic heart disease and valvular heart disease
were also determined. Comorbid conditions included
those coded in the secondary diagnosis fields of the index
discharge abstract or in the primary or secondary diagno-
sis fields from the discharge abstracts of hospitalizations
that occurred up to five years prior to the index event.
Based on the cardiovascular disease history obtained from
the discharge abstracts, each HF case was associated with
an underlying etiology according to the hierarchy of (1) is-
chemic heart disease, (2) valvular heart disease, (3) hyper-
tension, or (4) other/unknown diseases, resulting in four
mutually exclusive groups [11].
Pharmacotherapy
We linked our cohort to the Ontario Drug Benefit Data-
base to determine the percentage of Chinese and non-
Chinese patients 65 years of age or older who received at
least one prescription for a given medication relevant to
HF management within 90 days of discharge. Rates of
medications filled within 90 days prior to the index admis-
sion were also determined for the two groups.
Adherence
We compared the proportions of Chinese and non-
Chinese patients demonstrating high adherence to ACE
inhibitors, ARBs and beta-blockers. Adherence was esti-
mated using data available from 1998 onwards from the
Ontario Drug Benefit Database. Only patients who initiated
therapy within 30 days of discharge were included in the
analysis since they were the most likely to require the
medication in the long-term. Adherence was measured by
determining the proportion of days covered by the medica-
tion prescriptions within 6-month and 1-year time frames
following discharge for the index HF hospitalization. The
numerator was the number of days of medication supplied
for each prescription after hospital discharge to six-months
or 1-year after the discharge date. The denominator was
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was filled and six-months or 1-year after the discharge
date. For patients who died before the 6-month or 1-year
end-points, the proportion of days between the date the
first prescription was filled and death for which a supply of
the medication was available was determined instead. A
high level of adherence was defined as ≥ 80% of days cov-
ered, a commonly used cut-off in clinical trials. A sensitiv-
ity analysis was also conducted excluding patients who
were prescribed the medication within 90 days prior to ad-
mission in order to focus primarily on adherence in pa-







Mean age, y 76.1 75.9 0.22
Female, % 53.0 51.2 0.20Case-fatality and readmission
We determined rates of case-fatality and readmission oc-
curring 30 days or 1 year post-discharge. Readmission due
primarily to HF was distinguished from all-cause readmis-
sion. A composite outcome, measuring the rate of either
death or readmission for HF, was also determined. Case-
fatality included death for any reason, while readmission
represented at least one non-elective hospitalization after
the first admission. The number of deaths occurring in our
cohort was determined by linkage to the Ontario Registered
Persons Database.Charlson-Deyo Comorbidity Index
Mean score 1.85 1.77 0.10
Cardiovascular comorbidities, %
Acute myocardial infarction 17.7 23.4 <0.001
Atrial fibrillation/flutter 30.2 30.9 0.59
Cerebrovascular disease 11.6 12.2 0.50
Hypertension 51.8 42.3 <0.001
Peripheral vascular disease 5.0 9.1 <0.001
Valvular heart disease 17.6 14.4 0.001
Other comorbidities, %
Cancer, metastatic 2.2 2.0 0.67
Cancer, primary 4.9 6.6 0.011
Dementia 4.9 5.9 0.093








Rheumatologic diseases 1.0 2.1 0.006
HF etiology, %
Ischemic heart disease 35.3 47.7 <0.001
Valvular heart disease 11.6 7.2
Hypertension 26.1 16.1
Unknown/other 27.1 28.9Statistical analysis
All rates were reported as the number of events per 100
patients. Crude rates in the Chinese group were com-
pared to those in the non-Chinese group using the chi-
square test. Logistic regression modeling was used to ad-
just for patient level characteristics that might confound
the comparison of clinical outcomes. The variables in-
cluded in the risk-adjustment models were modified
from previously developed models based on medical ad-
ministrative claims in the United States. The mortality
model included 23 candidate predictors for mortality as-
sociated with age, sex and co-morbid diseases [12]. The
readmission model included 36 candidate predictors of
readmission for HF patients [13] (see Additional file 1
for model covariates). The composite outcome of mor-
tality or readmission was adjusted using variables from
the mortality risk adjustment model. A model predictor
was considered present if it was coded as a main, sec-
ondary or pre-admit diagnosis for any acute inpatient
hospitalization in the past five years. Adjusted clinical
outcomes for each group were considered to be signifi-
cantly different from the rate of all patients if the overall
crude rate did not fall within the 95% confidence limits
of the adjusted rate. All statistical analyses and data link-
ages were conducted using SAS release 9.1.
The research was approved by the Research Ethics
Board of Sunnybrook Health Sciences Centre.Results
Clinical characteristics
We identified 99,278 patients residing in an urban area
who were hospitalized in Ontario for the first time with
a most responsible diagnosis of HF from April 1, 1995
to March 31, 2008. Of these patients, 1,339 (1.3%) were
classified as Chinese based on their surname. The mean
age of the Chinese group was 76.1 years compared
to 75.9 years for the non-Chinese group (p = 0.22)
(Table 1). Female patients accounted for 53.0% of the
Chinese group and 51.2% of the non-Chinese group (p =
0.20). The mean Charlson-Deyo comorbidity index score
was similar between the two groups (p = 0.10). Of note,
Chinese patients demonstrated a higher prevalence of dia-
betes in general (23.5% vs. 20.0%, p < 0.001) and diabetes
with chronic complications (14.0% vs. 10.1%, p < 0.001).
Chronic obstructive pulmonary disease was markedly
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Chinese patients (22.3% vs. 13.4%, p < 0.001).
Among cardiovascular comorbidities, a greater propor-
tion of non-Chinese patients had been previously diag-
nosed with acute myocardial infarction (23.4% vs. 17.7%,
p < 0.001) and peripheral vascular disease (9.1% vs. 5.0%,
p < 0.001) (Table 1). Conversely, Chinese patients dis-
played a higher prevalence of valvular heart disease
(17.6% vs. 14.4%, p = 0.001) and hypertension (51.8% and
42.3%, p < 0.001).
The two groups also exhibited differences in the distri-
bution of HF etiology. HF was associated with ischemic
heart disease in a greater proportion of non-Chinese pa-
tients than Chinese patients (47.7% vs. 35.3%, p < 0.001)
(Table 1). A larger percentage of Chinese patients experi-
enced HF caused by valvular heart disease (11.6% vs. 7.2%
p < 0.001) or hypertension (26.1% vs. 16.1%, p < 0.001).
Pharmacologic management
Rates of HF medications prescribed within 90 days of dis-
charge were determined for all patients 65 years of age or
over. Chinese patients were less frequently prescribed
ACE inhibitors (57.5% vs. 66.4%, p < 0.001) but more fre-
quently prescribed ARBs (17.4% vs. 8.9%, p < 0.001) com-
pared to non-Chinese patients (Table 2). A greater








ACE inhibitors 57.5 66.4 <0.001
ARBs 17.4 8.9 <0.001
ARBs and ACE inhibitors 6.1 2.9 <0.001
ARBs or ACE inhibitors 68.8 72.4 0.011
Amiodarone 9.1 8.3 0.37







COX-2 inhibitors 3.2 2.8 0.48
Digoxin 29.4 36.1 <0.001




Spironolactone 12.6 15.0 0.033
Statins 27.6 25.9 0.22
Vasodilators 42.6 42.9 0.87
Warfarin 27.6 28.3 0.62inhibitors and ARBs (6.1% vs. 2.9%, p < 0.001) within
90 days of discharge. The tendency to prescribe either
ACE inhibitors or ARBs was higher among non-Chinese
patients (72.4% vs. 68.8%, p = 0.011). In addition, Chinese
patients were less frequently prescribed digoxin, furosem-
ide, and spironolactone but were more frequently pre-
scribed second-generation calcium channel blockers.
Prescribing rates for beta-blockers were comparable be-
tween the two groups.
Rates of medication prescribed up to 90 days prior to
the index admission were also examined to determine
whether the differences in use of ACE inhibitors and
ARBs after discharge existed before hospitalization.
Chinese patients were less frequently prescribed ACE in-
hibitors (35.7% vs. 39.6%, p = 0.011) and more frequently
prescribed ARBs (14.8% vs. 7.6%, p < 0.001) before the
first episode of HF requiring hospitalization (Table 3).
Chinese patients were also more likely to have been pre-
scribed both an ACE inhibitor and an ARB within the
90-days prior to the index event (2.9% vs. 1.6%, p <
0.001), a trend that persisted after hospitalization.
We determined the percentage of patients prescribed
ACE inhibitors, ARBs, or beta-blockers within 30-days
of discharge who achieved high long-term adherence to
these medications (Table 4). Compared to Chinese pa-
tients, non-Chinese patients demonstrated higher ad-
herence to ACE inhibitors over the one-year period
following the time when the first post-discharge pre-
scription was filled (76.7% vs. 67.6%, p < 0.001). In con-
trast, high adherence to ARBs was more common
among Chinese patients, though this difference was not
statistically significant (79.0% vs. 76.0%, p = 0.44). Beta-
blocker adherence after one year was similar between
the two different groups.
We conducted a sensitivity analysis in which we ex-
cluded patients who were prescribed these medications
up to 90 days prior to the index admission in order to
assess adherence among new users of the medications.
The results of this analysis were similar to the overall
adherence analysis, however, the gap in adherence rates
between Chinese and non-Chinese patients for ACE in-








ACE inhibitors 35.7 39.6 0.011
ARBs 14.8 7.6 <0.001
ARBs and ACE inhibitors 2.9 1.6 <0.001
ARBs or ACE inhibitors 47.6 45.7 0.22
Table 4 Proportion of patients displaying high adherence* to medications after discharge
High adherence within 6 months
of filling the first prescription
High adherence within 1 year
of filling the first prescription
Chinese Non-Chinese P Chinese Non-Chinese P
n(%) n(%) n(%) n(%)
Patients prescribed medication within 30 days of discharge
ACE inhibitors 286 (74.7) 25,328 (82.4) <0.001 259 (67.6) 23,568 (76.7) <0.001
ARBs 102 (82.3) 3428 (81.4) 0.81 98 (79.0) 3201 (76.0) 0.44
Beta blockers 252 (78.5) 17,208 (81.3) 0.21 242 (75.4) 16,319 (77.1) 0.48
*High adherence is defined as having prescriptions filled to cover at least 80% of days during the 6-month and 1-year periods following discharge.
Table 5 Case-fatality and readmission rates
Chinese Non-Chinese P
Case-fatality rate, %
n, all patients 1,339 97,939
At 30 days
Crude, % 12.3 10.9 0.10
Risk-adjusted, % (95% CI) 12.3 (10.7-13.9) 10.9 (10.7-11.0) -
At 1 year
Crude, % 31.7 30.2 0.24
Risk-adjusted, % (95% CI) 31.3 (29.1-33.6) 30.2 (29.9-30.5) -
Readmission rate, %
n, discharged alive 1,211 89,022
For HF
At 30 days
Crude, % 5.2 6.0 0.23
Risk-adjusted, % (95% CI) 5.1 (3.8-6.4) 6.0 (5.9-6.2) -
At 1 year
Crude, % 16.6 19.4 0.014
Risk-adjusted, % (95% CI) 16.4 (14.2-18.6)† 19.4 (19.2-19.7) -
For any reason
At 30 days
Crude, % 16.2 16.5 0.80
Risk-adjusted, % (95% CI) 16.1 (14.1-18.2) 16.5 (16.2-16.7) -
At 1 year
Crude, % 50.0 51.5 0.28
Risk-adjusted, % (95% CI) 49.8 (47.0-52.5) 51.5 (51.2-51.9) -
Composite rate, %*
n, all patients 1339 97,939
At 30 days
Crude, % 16.6 16.0 0.58
Risk-adjusted, % (95% CI) 16.2 (14.3-18.1) 16.0 (15.8-16.2) -
At 1 year
Crude, % 41.4 42.0 0.65
Risk-adjusted, % (95% CI) 41.0 (38.5-43.5) 42.0 (41.7-42.3) -
*Composite rate defined as the rate of death or readmission for heart failure.
† Statistically significantly lower than the overall rate.
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Chinese and non-Chinese patients displayed comparable
crude case-fatality rates at 30 days (12.3% vs. 10.9%, p =
0.10) and at 1 year (31.7% vs. 30.2%, p = 0.24) following
the index admission (Table 5). Among patients who sur-
vived to discharge, little difference was observed in
the crude rate of readmission for HF at 30 days (5.2% in
Chinese patients vs. 6.0% in non-Chinese patients, p =
0.23). However, Chinese patients were readmitted notice-
ably less frequently for HF at 1 year (16.6% vs. 19.4%, p =
0.014). Nevertheless, such a difference between Chinese
and non-Chinese patients did not carry forward to the
crude rates of readmission for any reason at 30 days
(16.2% vs. 16.5%, p = 0.80) and at 1 year (50.0% vs. 51.5%,
p = 0.28). Overall, Chinese and non-Chinese patients ex-
hibited a similar event rate of either death or readmission
for any reason at 30 days (16.6% vs. 16.0%, p = 0.58) and at
1 year (41.4% vs. 42.0%, p = 0.65).
Similar trends were observed after risk-adjustment.
The one-year risk-adjusted rate of readmission for HF
among Chinese patients (16.4%; 95% CI: 14.2%-18.6%)
was statistically significantly lower than the overall crude
rate for all patients. The risk-adjusted rates for the other
outcomes were not significantly different from the over-
all rate.
Immigration status analysis
Through linkage to the Canadian Permanent Resident
Database, we identified that approximately 30% (n = 391)
of the Chinese heart failure patients were relatively re-
cent immigrants to Ontario having immigrated after
1984, as compared with only 3% (n = 3,640) of the non-
Chinese patients in the study cohort. A majority of the
recent Chinese immigrants came from China (71%)
while 12% came from Hong Kong and the rest from
other countries. A sensitivity analysis showed that recent
Chinese immigrants were slightly younger than longer-
term Chinese residents of Ontario (75 vs 77 years mean
age), but otherwise, the causes of heart failure, medical
management, and long-term outcomes were similar be-
tween the two groups (data not shown but available
upon request).
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In the current study of Chinese and non-Chinese patients
with an index hospitalization for HF, we found significant
differences in HF etiology and pharmacotherapy. Among
Chinese patients, HF was less commonly associated with
ischemic heart disease and more commonly due to hyper-
tension and valvular etiologies. Chinese patients were less
frequently prescribed ACE inhibitors and more frequently
prescribed ARBs. In addition, Chinese patients who were
prescribed ACE inhibitors were less adherent to ACE in-
hibitors over a 1-year follow-up period. Despite these dif-
ferences, 1-year mortality outcomes between the Chinese
and non-Chinese patients were similar.
The finding that ischemic heart disease was a more
common cause of HF in non-Chinese patients compared
to Chinese patients may be a reflection of the consistently
lower rate of ischemic heart disease observed among
Chinese individuals as compared to other ethnic groups
living in Canada or the United States [3,12,13]. Hyperten-
sion and valvular heart disease were relatively more com-
mon sources of HF in Chinese patients than non-Chinese
patients [14,15]. Older Chinese immigrants to Canada
may not have had access to good hypertension and/or
rheumatic heart disease screening and treatment in China.
Previous studies from Asia have also pointed to hyperten-
sion as the most important risk factor among Chinese pa-
tients suffering from HF [16,17]. Our finding that the
causes of heart failure were similar, regardless of whether
a Chinese HF patient was a recent immigrant or longer-
term resident of Ontario, suggests that there are true bio-
logical differences between Chinese and non-Chinese
heart failure patients.
The higher rate of hypertension along with the lower
rate of ischemic heart disease may signify a greater preva-
lence of HF with preserved systolic function among
Chinese patients. Patients with preserved ejection fraction
are more likely to have hypertension and less likely to have
ischemic heart disease than patients with reduced ejection
fraction [11,18,19]. In a tertiary care cardiology clinic in
Toronto, a greater proportion of Chinese patients than
white patients with HF were indeed found to have a pre-
served ejection fraction [3]. A study of Chinese patients in
Hong Kong similarly showed that HF with normal systolic
function was more common than heart failure due to sys-
tolic dysfunction [20]. Unfortunately, our study was lim-
ited by the lack of data on ejection fraction.
In our current study, we found that a lower proportion
of Chinese patients were prescribed ACE inhibitors both
before hospital admission and after discharge. A high in-
cidence of cough has been reported in Chinese patients
on ACE inhibitors in studies from Asia [21,22] though
one study has refuted this claim [23]. The higher propor-
tion of Chinese patients who were prescribed ARBs, or
both ARBs and ACE inhibitors, could be due to actualintolerance to ACE inhibitors or a general perception
among physicians that Chinese patients will be more
likely to experience an associated cough. The lower ad-
herence to ACE inhibitors observed among the Chinese
patients supports the former hypothesis.
Rates of case-fatality and readmission were similar be-
tween the two groups. One exception was the lower 1-
year rate of readmission for HF among Chinese patients
despite the comparable case-fatality rates and rates of re-
admission for any reason. The reasons for this finding
are uncertain from this study and warrant further inves-
tigation. The outcomes in this study stand in contrast to
a study conducted using administrative databases from
Alberta in which Chinese HF patients had a higher ad-
justed 1-year mortality rate than White or South Asian
patients [5]. The authors of that study could not identify
the reason for their observation but the differences be-
tween these two studies could reflect differences in the
types of Chinese HF patients in the two provinces with
HF patients of Chinese descent in Alberta being sicker
than those in Ontario. COPD rates, a reflection of smok-
ing rates, were noticeably higher in Chinese relative to
non-Chinese patients in Alberta whereas the reverse was
noted in the Ontario data. Other factors (e.g. socioeco-
nomic status, access to health care, time since immigra-
tion) may also contribute to the disparate findings and
warrant further investigation.
Our study has several limitations. First, we identified
patients as Chinese or non-Chinese based on a validated
list of Chinese surnames rather than self-reported ethni-
city, and some participants may have been misclassified.
Second, we could not identify from the linked adminis-
trative databases whether the participants had preserved
or reduced ejection fraction, and we had limited data re-
garding other patient characteristics and in-hospital HF
management as would be contained in a heart failure
clinical registry. Third, we could not identify why Chinese
patients were less likely to adhere to ACE inhibitors
although it was likely due in part to cough and intolerance.
Despite these limitations, this is one of largest studies of the
real-world outcomes of HF patients of Chinese descent
conducted outside of Asia, and provides important
comparative information that may be of use to clinicians
treating such patients in various clinical settings around
the world.
Conclusion
In conclusion, there are significant differences in HF eti-
ology and the medications used to manage HF between
Chinese and non-Chinese patients experiencing their
first HF event requiring hospitalization. Future research
efforts should investigate why these differences exist and
what strategies could improve outcomes for patients
with HF in different ethnic groups.
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